Patents by Inventor Wulan Deng

Wulan Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220202958
    Abstract: Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a polynucleotide encoding: i) a 5? long terminal repeat (LTR) and a self-inactivating 3? LTR; ii) at least one polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured such that the WPRE does not integrate into a target genome; and vii) a sequence that is a reverse complement of a sequence encoding human beta-globin, and can include beta-globin that has a ?T87Q mutation. Intron 2 of the beta globin gene can be a complete intron. Modified erythrocyte progenitor cells, recombinant vectors and virions comprising recombinant polynucleotides, and methods of making the vectors and virions are included.
    Type: Application
    Filed: March 15, 2022
    Publication date: June 30, 2022
    Inventors: Stefano Rivella, Laura Breda, Alisa Dong, Gerd Blobel, Wulan Deng
  • Patent number: 11311632
    Abstract: Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a poly-nucleotide encoding: i) a 5? long terminal repeat (LTR) and a self-inactivating 3? LTR; ii) at least one polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured such that the WPRE does not integrate into a target genome; and vii) a sequence that is a reverse complement of a sequence encoding human beta-globin, and can include beta-globin that has a PT87Q mutation. Intron 2 of the beta globin gene can be a complete intron. Modified erythrocyte progenitor cells, recombinant vectors and virions comprising recombinant polynucleotides, and methods of making the vectors and virions are included.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 26, 2022
    Assignees: CORNELL UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Stefano Rivella, Laura Breda, Alisa Dong, Gerd Blobel, Wulan Deng
  • Patent number: 11174507
    Abstract: Labeled probes, and methods of use thereof, comprise a Cas polypeptide conjugated to gRNA that is specific for target nucleic acid sequences, including genomic DNA sequences. The probes and methods can be used to label nucleic acid sequences without global DNA denaturation.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 16, 2021
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Robert Singer, Timothee Lionnet, Wulan Deng
  • Patent number: 11174506
    Abstract: Labeled probes, and methods of use thereof, comprise a Cas polypeptide conjugated to gRNA that is specific for target nucleic acid sequences, including genomic DNA sequences. The probes and methods can be used to label nucleic acid sequences without global DNA denaturation. The presently-disclosed subject matter meets some or all of the above identified needs, as will become evident to those of ordinary skill in the art after a study of information provided in this document.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: November 16, 2021
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Robert Singer, Wulan Deng, Timothee Lionnet
  • Publication number: 20190330678
    Abstract: Labeled probes, and methods of use thereof, comprise a Cas polypeptide conjugated to gRNA that is specific for target nucleic acid sequences, including genomic DNA sequences. The probes and methods can be used to label nucleic acid sequences without global DNA denaturation.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 31, 2019
    Inventors: Robert Singer, Timothee Lionnet, Wulan Deng
  • Patent number: 10329333
    Abstract: Methods and compositions for controlling gene expression are disclosed.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: June 25, 2019
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Gerd Blobel, Wulan Deng
  • Publication number: 20180051059
    Abstract: Methods and compositions for controlling gene expression are disclosed.
    Type: Application
    Filed: October 17, 2017
    Publication date: February 22, 2018
    Inventors: Gerd Blobel, Wulan Deng
  • Publication number: 20180008725
    Abstract: Provided are compositions and methods for inducing expression of human beta-globin in erythrocytes for use in prophylaxis and/or therapy of a hemoglobinopathy in an individual. The method generally entails introducing into CD34+ cells a polynucleotide encoding: i) a 5? long terminal repeat (LTR) and a self-inactivating 3? LTR; ii) at least one polyadenylation signal; iii) at least one promoter; iv) a globin gene locus control region (LCR); v) an ankyrin insulator element (Ank); vi) a Woodchuck Post-Regulatory Element (WPRE) configured such that the WPRE does not integrate into a target genome; and vii) a sequence that is a reverse complement of a sequence encoding human beta-globin, and can include beta-globin that has a PT87Q mutation. Intron 2 of the beta globin gene can be a complete intron. Modified erythrocyte progenitor cells, recombinant vectors and virions comprising recombinant polynucleotides, and methods of making the vectors and virions are included.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 11, 2018
    Inventors: Stefano RIVELLA, Laura BREDA, Alisa DONG, Gerd BLOBEL, Wulan DENG
  • Patent number: 9815877
    Abstract: Methods and compositions for controlling gene expression are disclosed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 14, 2017
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Gerd Blobel, Wulan Deng
  • Publication number: 20170268035
    Abstract: Labeled probes, and methods of use thereof, comprise a Cas polypeptide conjugated to gRNA that is specific for target nucleic acid sequences, including genomic DNA sequences. The probes and methods can be used to label nucleic acid sequences without global DNA denaturation. The presently-disclosed subject matter meets some or all of the above identified needs, as will become evident to those of ordinary skill in the art after a study of information provided in this document.
    Type: Application
    Filed: October 16, 2015
    Publication date: September 21, 2017
    Inventors: Robert SINGER, Wulan DENG, Timothee LIONNET
  • Publication number: 20150152151
    Abstract: Methods and compositions for controlling gene expression are disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: June 4, 2015
    Inventors: Gerd Blobel, Wulan Deng